Educational Purposes Only: This website is for educational purposes only. All products are in the pre-clinical development stage. No content contained herein has been reviewed by the FDA.  Full Disclaimer →

Reg D · Rule 506(b) · Accredited Investors Only

The Category Is Being Written Right Now

Strategic acquirers — Hologic, Intuitive Surgical, Stryker, Medtronic — are actively paying premium multiples for women's health device platforms. NEG+ Innovations is building squarely in their acquisition lane with a physician-designed, IP-protected, reimbursement-ready precision technology platform. Women's health is not a niche. It is one of the largest, least-penetrated markets in all of medicine.

Request Investor Brief Access Data Room
~$16.2B
Combined US TAM · Four-Device Platform
~$1B–$2.1B
Platform Exit Range · 5–11× Rev Multiple
~$189M
Year-5 Platform Revenue · ~71% Blended GM
11
Strategic Acquirer Targets · Two Distinct Pools
Investment Thesis

Why NEG+ Innovations

Six structural advantages that differentiate NEG+ from typical pre-revenue medtech investments at the same stage — each grounded in clinical credibility, regulatory preparedness, and capital efficiency.

01 · Physician-Led Design

The Inventor Is the Surgeon

Every device emerged from a gap Dr. Belotte encountered firsthand — in the operating room, the labor suite, and the clinic. Each need was validated through voice-of-customer research before a single patent was filed. No translation required between clinical insight and engineering solution. No product-market fit risk.

02 · Portfolio Architecture

Four Devices. Two Acquirer Pools. One Exit Thesis.

A cross-life-stage platform spanning labor & delivery, minimally invasive gynecologic surgery, urogynecology, and pelvic pain. Two structurally distinct strategic-acquirer pools — maternal-fetal monitoring majors and gynecologic surgery leaders — with single-device divestiture optionality preserved at every product level.

03 · Non-Dilutive Capital

NIH SBIR/STTR as an Equity Shield

NIH SBIR and STTR grants are pursued in parallel with private capital — delivering independent federal peer-review validation of core technology at zero dilution to investors. Every non-dilutive dollar awarded extends runway, protects equity, and strengthens the diligence record heading into Series A.

04 · Founder Alignment

Identical Terms. Shared Risk. Full Conviction.

Dr. Belotte co-invests personally on identical economic terms alongside every outside investor — no separate founder pricing, no preferred economics. Capital conviction is demonstrated in cash, not only sweat equity. Investor and founder interests are fully aligned from the first dollar raised.

05 · Regulatory Readiness

The Path Is Mapped — and We Are On It Today

FDA 510(k) strategy is defined, predicate analysis is complete, and specialized regulatory counsel is engaged. Pre-Submission Q-Sub meetings are scheduled. The founder's clinical development experience at GlaxoSmithKline Oncology brings industry-grade regulatory discipline directly to our program execution.

06 · Tax Efficiency

QSBS — Up to 100% Federal Capital Gains Exclusion

NEG+ is a Delaware C-Corp structured for Qualified Small Business Stock eligibility under IRC §1202. Investors entering at this stage may qualify for up to 100% federal exclusion on qualifying gains — a material tax advantage that is unavailable at later funding rounds.

Capital Structure

Deal Terms & Structure

NEG+ is raising its initial Seed round via SAFE instrument under Reg D Rule 506(b), open exclusively to verified accredited investors. Full term sheet and financial model available upon execution of NDA.

Current Round — Seed

Instrument SAFE (Simple Agreement for Future Equity)
Regulation Reg D, Rule 506(b) — Accredited Investors Only
Target Close 2026 — Milestone-Linked Tranches
Use of Proceeds Engineering, IP, NIH Grant Development, Clinical Prep
Minimum Investment Available Upon NDA Execution
Valuation Cap / Discount Available Upon NDA Execution

Structural Protections

Entity Delaware C-Corporation
IP Ownership All IP formally assigned to and vested in the C-Corp
Cap Table Clean — individual founder, investor-ready
QSBS Eligibility Yes — IRC §1202, up to 100% federal exclusion
Founder Co-Investment Identical terms — no founder preference
Subsequent Rounds Series Seed → Series A (milestone-gated)

Investor Companion — Edition 2 · Available Upon Request

Accredited investors may request our full Investor Companion (Edition 2 — MUMS Integrated) including updated market sizing (~$16.2B combined TAM), acquirer map, capital deployment schedule, and SAFE term sheet.

Request Investor Brief →

Offered under Regulation D, Rule 506(b) to verified accredited investors only. This is not an offer to sell securities.

Development Roadmap

Capital Deployment Milestones

Each round of capital is tied to defined regulatory and technical inflection points — providing investors clear de-risking benchmarks and sequential value creation events.

Milestone Device / Program Target Timeline Round
Pre-clinical feasibility — bench prototype validation Belotte Colpotomizer™ · PNB Device™ 2026 Seed
NIH STTR Phase I Specific Aims submission POP-Q AutoSense™ 2026 NIH
MUMS™ ISA + SaMD concept design · SBIR Phase I preparation MUMS™ 2026 Seed
Patent filings — provisional to PCT conversion Full Portfolio 2026 Seed
ISO 13485 QMS implementation · Design History File initiation Belotte Colpotomizer™ 2026–2027 Seed
IDE submission — first-in-human feasibility study Belotte Colpotomizer™ · PNB Device™ 2026–2027 Seed
FDA 510(k) submission — Belotte Colpotomizer™ Belotte Colpotomizer™ 2027–2028 Series A
NIH STTR Phase I award + clinical validation study initiation POP-Q AutoSense™ 2027 NIH
FDA 510(k) clearance — Belotte Colpotomizer™ (commercial launch) Belotte Colpotomizer™ 2028 Series A
MUMS™ pivotal clinical trial initiation (De Novo / PMA pathway) MUMS™ 2028–2030 Series A+
Platform exit / strategic acquisition or IPO target Full Portfolio · 11-Acquirer Pool 2028–2031 Series A+
Investment team reviewing financial projections and milestone data
Capital Deployment
Milestone-Linked. Founder-Aligned.

Every dollar raised is tied to a defined regulatory or technical inflection point — with the founder co-investing on identical terms alongside every investor.

Capital Allocation

Use of Proceeds

Seed capital deployed across four priority areas — optimized for maximum milestone velocity and de-risking per dollar.

35%
Engineering & Prototyping

Bench prototype validation for Colpotomizer™ and PNB Device™ · ISO 13485 QMS · Design History File

20%
Intellectual Property

Provisional-to-PCT conversion · Freedom-to-operate analysis · All four programs

20%
NIH Grant Development

STTR Phase I Specific Aims (POP-Q AutoSense™) · SBIR Phase I (PNB Device™) · Academic PI engagement

25%
Clinical & Operations

Pre-IDE meetings · IRB preparation · KOL engagement · Working capital reserve

Get In Touch

Connect With Our Team

Accredited investors and institutional partners are encouraged to reach out directly. All inquiries are held in strict confidence.

Investor Inquiries
investors@negplus.com
For accredited investor inquiries, term sheet requests, and investor brief access
General & Partnership
info@negplus.com
Strategic partnerships, clinical collaborations, and general inquiries
Headquarters
Weston, Massachusetts
Delaware C-Corp · Greater Boston MedTech Corridor
⏱️
Response Time
Within 48 Business Hours
All investor inquiries are reviewed by the founding team directly

Request Data Room Access

Complete the form below to request access to our secure investor data room. Available to verified accredited investors only under Reg D Rule 506(b).

Already have access? Sign In →
All inquiries are handled with strict discretion. NEG+ Innovations does not share investor contact information with any third party.

This page is for informational purposes only and does not constitute an offer to sell or solicitation to buy securities. Offered under Regulation D, Rule 506(b) to verified accredited investors only.